Silence Therapeutics plc SLN
At closeNov 3, 2026, 4:20 PM EST
After hours · Nov 3, 4:20 PM ET
- YTD
- +225.33%
- 1 year
- +199.24%
- Market cap
- 1.23B
- Revenue (ttm)
- 615.00K
- EPS (ttm)
- -1.29
- Shares out
- 62.20M
- Forward P/E
- -52.05
- YTD return
- +225.33%
- 1-year return
- +199.24%
- Volume
- 352.41K
- Avg volume
- 2.78M
- Open
- 19.78
- Previous close
- 19.76
- Day's range
- 19.78 – 19.80
- 52-week range
- 4.19 – 19.87
- Beta
- 1.34
- Analysts
- Hold
- Price target
- 19.75 (-0.2%)
- Earnings date
- Nov 5, 2026
15m -0.03 (-0.15%)
Key statistics
- Enterprise value
- 861.65M
- PEG ratio
- 0.00
- Price / sales
- 2000.61
- Price / book
- 24.30
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -23.57M
- Total cash
- 72.05M
- Total debt
- 112.00K
- Return on equity
- -90.41%
- Short % of float
- 5.78%
- 50-day average
- 13.61
- 200-day average
- 9.13
Analyst view
Consensus: hold
- Target (low)
- 19.00
- Target (mean)
- 19.75
- Target (high)
- 20.00
- Strong buy0
- Buy1
- Hold4
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate -0.09.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | -0.11289 | — | — | — |
| Aug 10, 2026 | Jun 30, 2026 | -0.13866 | -0.26 | -0.12 | -87.51% |
| May 7, 2026 | Mar 31, 2026 | -0.33 | -0.32 | +0.01 | +3.03% |
| Mar 5, 2026 | Dec 31, 2025 | -0.32 | -0.25 | +0.07 | +21.88% |
| Nov 6, 2025 | Sep 30, 2025 | -0.40 | -0.45 | -0.05 | -12.50% |
| Aug 7, 2025 | Jun 30, 2025 | -0.27 | -0.54 | -0.27 | -100.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 21, 2026 | HC Wainwright & Co. | down | Buy | Neutral |
| Aug 11, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Jun 24, 2026 | Cantor Fitzgerald | init | — | Overweight |
| Jun 17, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 13, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 16, 2025 | HC Wainwright & Co. | reit | Buy | Buy |
About Silence Therapeutics plc
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- Website
- silence-therapeutics.com
News
Silence Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Silence Therapeutics plc - SLN 
HC Wainwright & Co. Downgrades Silence Therapeutics to Neutral, Lowers Price Target to $20 
Are BRZE, SLN, OPCH, RXO Obtaining Fair Deals for their Shareholders? 
Does Silence Therapeutics (SLN) Have the Potential to Rally 82.84% as Wall Street Analysts Expect? 
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Silence Therapeutics plc (Nasdaq – SLN), Option Care Health, Inc. (Nasdaq – OPCH), RXO Inc. (NYSE – RXO), Sangoma Technologies Corporation (Nasdaq – SANG) 
Nasdaq Jumps Over 1% As Tech Stocks Gain: Investor Sentiment Improves, Greed Index Remains In ‘Extreme Fear’ Zone 
Amazon.com, Cleveland-Cliffs, Disc Medicine, Silence Therapeutics and EyePoint: Why These 5 Stocks Are on Investors' Radars Today 
Crude Oil Moves Higher; US Homebuilder Sentiment Falls In October 
12 Health Care Stocks Moving In Monday's Intraday Session 
Why Is Silence Therapeutics Stock Skyrocketing Monday?
Your note
Sign in to keep a note on SLN — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Siren, L.L.C. | 5.50% | 3,311,438 | 65.50M | Jun 29, 2026 |
| TCG Crossover Management, LLC | 5.04% | 3,033,560 | 60.00M | Jun 29, 2026 |
| Redmile Group, LLC | 3.60% | 2,164,777 | 42.82M | Jun 29, 2026 |
| Nantahala Capital Management, LLC | 2.24% | 1,346,731 | 26.64M | Jun 29, 2026 |
| Citadel Advisors Llc | 2.21% | 1,329,625 | 26.30M | Jun 29, 2026 |
| Nextech Invest, Ltd. | 1.58% | 952,400 | 18.84M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 3.39% | 2,042,900 | 40.41M | Aug 30, 2026 |
| Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund | 0.88% | 531,788 | 10.52M | Aug 30, 2026 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 0.83% | 500,000 | 9.89M | Aug 30, 2026 |
| iShares Trust-iShares Biotechnology ETF | 0.48% | 289,972 | 5.74M | Sep 29, 2026 |
| Fidelity Advisor Series VII-Fidelity Advisor Health Care Fund | 0.38% | 228,000 | 4.51M | Aug 30, 2026 |
| ALGER FUNDS-Alger Small Cap Growth Fund | 0.18% | 105,679 | 2.09M | Jul 30, 2026 |